The Influence of HIV-1 Subtype in the Response to Therapeutic Dendritic Cell Vaccine



Valéria Ferreira1, Patrícia Moura2, Sergio Crovella1, Ricardo Sobhie Diaz* , 3, Adauto Castelo Filho3, Ricardo Ximenes3, Luiz Cláudio Arraes3
1 Universidade Federal de Pernambuco, Recife (PE), Brazil
2 Instituto de Ciências Biológicas, Universidade de Pernambuco, Recife, PE, Brazil
3 Paulista School of Medicine, Federal University of Sao Paulo, R. Pedro de Toledo, 781, Sao Paulo, SP – 04039-000, Brazil


Article Metrics

CrossRef Citations:
5
Total Statistics:

Full-Text HTML Views: 215
Abstract HTML Views: 212
PDF Downloads: 62
Total Views/Downloads: 489
Unique Statistics:

Full-Text HTML Views: 149
Abstract HTML Views: 138
PDF Downloads: 55
Total Views/Downloads: 342



© Ferreira et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Paulista School of Medicine, Federal University of Sao Paulo, R. Pedro de Toledo, 781, Sao Paulo, SP – 04039-000, Brazil; Tel: (55-11) 9109-0445; Fax: (55-11) 4192-3176; E-mail: rsdiaz@catg.com.br


Abstract

In the present study, we investigated the influence of HIV-1 subtype in the response to the dendritic cell (DC) therapeutic vaccine for HIV. HIV-1 viral load and TCD8+/TCD4+ cell counts for up to 48 weeks after vaccination. Out of 19 immunized subjects, 13 were infected by subtype B, 5 by subtype F, and 1 by subtype D. Overall, 42.1% (8/19) achieved a viral load decline of ≥ 1 log10 sustained up to 48 weeks after immunization. Such magnitude of viral load drop was seen in 80% (4/5) of subtype F infected patients, and in 23.0% (3/13) of the subtype B infected ones (p=0.08). Moreover, mean viral load decline was 1.32 log10, for subtype F infected individuals compared to 0.5 log10 among subtype B infected patients (p=0.01). The variation in TCD4+ cell count was not related to HIV-1 subtype. Larger studies are necessary to confirm the efficacy of this immunotherapy and the differential response according to the background genetic diversity of HIV-1.

Keywords: Dendritic cells, HIV-1 subtype, vaccine, immunotherapy..